Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076076 · ClinicalTrials.gov registry record · Phase 3
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 822
- Enrollment target
NCT00076076 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 822 participants.
The verdict
NCT00076076, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 822 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
Interventions
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076076
The ClinicalTrials.gov registry entry for NCT00076076 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roflumilast is the first listed.
NCT00076076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076076 about?
NCT00076076 is a clinical study titled "The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)". The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
What is the current status of trial NCT00076076?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 822 participants. The study started on 2003-12. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00076076?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT00076076?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.